Lucky Games, som designar, utvecklar och marknadsför kasinospel med olika teman och underhållningsvä...
Scanfil’s Q1 top line continued to grow at a 20% annual rate while operating margin remained decent ...
Evli and EAB have signed a letter of intent, pursuant to which the parties are looking into a potent...
Scanfil reported better net sales and better EBIT than market consensus (Refinitiv) expected in Q1.
Elanders presented a strong Q1 report with 2% group organic growth but EBIT growing by 29% y/y, whic...
SDS publicerade idag den 21 april 2022 bolagets delårsrapport för det första kvartalet 2022.
Idefirix has secured pricing and reimbursement in Sweden, the Netherlands and Germany, and on an ind...
Redeye expects to lower its fair value range thanks to soft sales, which were hurt by some delayed o...
Finnair reports Q1 results on Apr 27. The focus will be on the responses to the change which alters ...
Indexuppräkning i kombination med bra nettouthyrning medför stark tillväxt i hyresintäkterna inför 2...
Redeye adjusts BioArctic's valuation to reflect the terminated collaboration with AbbVie.
Redeye comments on Nanexa’s Q1 report and give our view of progress so far in 2022.
Detection Technology publishes its Q1 business review on April 27th.
Redeye is encouraged to see continued strong growth for the group in Q1, around 24% organic proforma...
Proptech-bolaget Compare-IT utvecklar och säljer styrsystemet Smart Homeline och smarta-hemtjänsten ...
Sdiptech's Q1 report is due on 29 April. We expect a solid quarter with 15% y/y sales growth and EBI...
Redeye is positive about the announcement of three new design wins, but states they were very much e...
Redeye leaves a comment on the announced rights issue and Q1 report published by Alzinova earlier th...
Redeye initiates coverage of Faron Pharmaceuticals, a Finnish biotech company focused on developing ...
Redeye endorses Coala Life receiving a new 510(k) approval for its Coala Heart Monitor to be used fo...
